vs
Side-by-side financial comparison of DIVERSIFIED HEALTHCARE TRUST (DHC) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
DIVERSIFIED HEALTHCARE TRUST is the larger business by last-quarter revenue ($379.6M vs $281.3M, roughly 1.3× Guardant Health, Inc.). DIVERSIFIED HEALTHCARE TRUST runs the higher net margin — -5.6% vs -45.7%, a 40.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -0.0%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-166.4M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 1.2%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
DHC vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $379.6M | $281.3M |
| Net Profit | $-21.2M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | -12.6% | -43.0% |
| Net Margin | -5.6% | -45.7% |
| Revenue YoY | -0.0% | 39.4% |
| Net Profit YoY | 75.7% | -15.8% |
| EPS (diluted) | $-0.09 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $379.6M | $281.3M | ||
| Q3 25 | $388.7M | $265.2M | ||
| Q2 25 | $382.7M | $232.1M | ||
| Q1 25 | $386.9M | $203.5M | ||
| Q4 24 | $379.6M | $201.8M | ||
| Q3 24 | $373.6M | $191.5M | ||
| Q2 24 | $371.4M | $177.2M | ||
| Q1 24 | $370.8M | $168.5M |
| Q4 25 | $-21.2M | $-128.5M | ||
| Q3 25 | $-164.0M | $-92.7M | ||
| Q2 25 | $-91.6M | $-99.9M | ||
| Q1 25 | $-9.0M | $-95.2M | ||
| Q4 24 | $-87.4M | $-111.0M | ||
| Q3 24 | $-98.7M | $-107.8M | ||
| Q2 24 | $-97.9M | $-102.6M | ||
| Q1 24 | $-86.3M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | -12.6% | -43.0% | ||
| Q3 25 | -43.4% | -37.3% | ||
| Q2 25 | -24.5% | -45.9% | ||
| Q1 25 | -2.7% | -54.6% | ||
| Q4 24 | -26.1% | -62.4% | ||
| Q3 24 | -26.5% | -61.3% | ||
| Q2 24 | -23.0% | -56.8% | ||
| Q1 24 | -23.7% | -59.2% |
| Q4 25 | -5.6% | -45.7% | ||
| Q3 25 | -42.2% | -35.0% | ||
| Q2 25 | -23.9% | -43.0% | ||
| Q1 25 | -2.3% | -46.8% | ||
| Q4 24 | -23.0% | -55.0% | ||
| Q3 24 | -26.4% | -56.3% | ||
| Q2 24 | -26.3% | -57.9% | ||
| Q1 24 | -23.3% | -68.2% |
| Q4 25 | $-0.09 | $-1.01 | ||
| Q3 25 | $-0.68 | $-0.74 | ||
| Q2 25 | $-0.38 | $-0.80 | ||
| Q1 25 | $-0.04 | $-0.77 | ||
| Q4 24 | $-0.37 | $-0.90 | ||
| Q3 24 | $-0.41 | $-0.88 | ||
| Q2 24 | $-0.41 | $-0.84 | ||
| Q1 24 | $-0.36 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $105.4M | $378.2M |
| Total DebtLower is stronger | $2.4B | $1.5B |
| Stockholders' EquityBook value | $1.7B | $-99.3M |
| Total Assets | $4.4B | $2.0B |
| Debt / EquityLower = less leverage | 1.47× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $105.4M | $378.2M | ||
| Q3 25 | $201.4M | $580.0M | ||
| Q2 25 | $141.8M | $629.1M | ||
| Q1 25 | $302.6M | $698.6M | ||
| Q4 24 | $144.6M | $525.5M | ||
| Q3 24 | $256.5M | $585.0M | ||
| Q2 24 | $265.6M | $933.7M | ||
| Q1 24 | $207.1M | $1.0B |
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $3.1B | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.7B | $-99.3M | ||
| Q3 25 | $1.7B | $-354.5M | ||
| Q2 25 | $1.9B | $-305.5M | ||
| Q1 25 | $1.9B | $-250.8M | ||
| Q4 24 | $2.0B | $-139.6M | ||
| Q3 24 | $2.0B | $-60.1M | ||
| Q2 24 | $2.1B | $-1.6M | ||
| Q1 24 | $2.2B | $68.3M |
| Q4 25 | $4.4B | $2.0B | ||
| Q3 25 | $4.7B | $1.3B | ||
| Q2 25 | $4.8B | $1.3B | ||
| Q1 25 | $5.0B | $1.3B | ||
| Q4 24 | $5.1B | $1.5B | ||
| Q3 24 | $5.3B | $1.5B | ||
| Q2 24 | $5.3B | $1.6B | ||
| Q1 24 | $5.3B | $1.7B |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.6M | $-26.4M |
| Free Cash FlowOCF − Capex | $-166.4M | $-54.2M |
| FCF MarginFCF / Revenue | -43.8% | -19.3% |
| Capex IntensityCapex / Revenue | 38.7% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-280.3M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.6M | $-26.4M | ||
| Q3 25 | $-49.3M | $-35.4M | ||
| Q2 25 | $53.0M | $-60.3M | ||
| Q1 25 | $-3.2M | $-62.7M | ||
| Q4 24 | $112.2M | $-64.5M | ||
| Q3 24 | $21.1M | $-51.1M | ||
| Q2 24 | $44.3M | $-94.0M | ||
| Q1 24 | $28.6M | $-30.3M |
| Q4 25 | $-166.4M | $-54.2M | ||
| Q3 25 | $-89.8M | $-45.8M | ||
| Q2 25 | $18.8M | $-65.9M | ||
| Q1 25 | $-42.9M | $-67.1M | ||
| Q4 24 | $-89.5M | $-83.4M | ||
| Q3 24 | $-26.1M | $-55.3M | ||
| Q2 24 | $3.3M | $-99.1M | ||
| Q1 24 | $-18.1M | $-37.2M |
| Q4 25 | -43.8% | -19.3% | ||
| Q3 25 | -23.1% | -17.3% | ||
| Q2 25 | 4.9% | -28.4% | ||
| Q1 25 | -11.1% | -33.0% | ||
| Q4 24 | -23.6% | -41.3% | ||
| Q3 24 | -7.0% | -28.9% | ||
| Q2 24 | 0.9% | -55.9% | ||
| Q1 24 | -4.9% | -22.1% |
| Q4 25 | 38.7% | 9.9% | ||
| Q3 25 | 10.4% | 3.9% | ||
| Q2 25 | 8.9% | 2.4% | ||
| Q1 25 | 10.2% | 2.2% | ||
| Q4 24 | 53.1% | 9.4% | ||
| Q3 24 | 12.6% | 2.2% | ||
| Q2 24 | 11.0% | 2.9% | ||
| Q1 24 | 12.6% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DHC
| Senior Housing Operating Portfolio Segment | $323.4M | 85% |
| Rental Income | $56.2M | 15% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
